Last reviewed 2026-04-20 · How we verify

Tagrisso

At a glance

Approved indications

• Non-small cell lung cancer, positive for epidermal growth factor receptor expression

Common side effects

• Leukopenia
• Lymphopenia
• Thrombocytopenia
• Anemia
• Diarrhea
• Rash
• Musculoskeletal pain
• Neutropenia
• Nail toxicity
• Dry skin
• Stomatitis
• Fatigue

Serious adverse events

• Serious adverse reactions (overall)
• Pneumonia

Key clinical trials

• Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (PHASE2)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (PHASE2)
• Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (PHASE1)
• Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (PHASE1)
• Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tagrisso CI brief — competitive landscape report
• Tagrisso updates RSS · CI watch RSS
• Suzhou Genhouse Bio Co., Ltd. portfolio CI